The Island Capsule is a publication of the PEI College of Pharmacy and is forwarded to every registrant of the College on the 1st and 3rd Fridays of the month.
Council Seeking Nominations
The Council of the PEI College of Pharmacy is seeking 2 nominations from registrants to fulfill the roles of a pharmacist and pharmacy technician on Council.
Serving as a Director on the Council of the PEI College of Pharmacy is an opportunity to play an important role in advancing the College’s legislated mandate to regulate the profession in the public interest. All Directors-pharmacists and pharmacy technicians elected by their peers and members of the public appointed by government – share a fiduciary duty to serve and protect the public interest through effective governance and a commitment to public accountability and service.
In accordance with the Regulated Health Professions Act and PEI College of Pharmacy Bylaws:
The following persons are not eligible for election or appointment to a council:
(a) a person who is, or was within the past year, a member of the governing body of an advocacy organization for the regulated health profession; or
(b) a person whose conduct was found, within the past year, to constitute professional misconduct or incompetence under the RHPA or in another jurisdiction; or
(c) a person who is a respondent in an ongoing complaint under the RHPA or in another jurisdiction.
Registrants interested in putting forward their name for nomination are directed to completed the Nomination Form below by Friday, November 18, 2022.
There will be an update to the PEICP Registrant Portal on Tuesday, November 29th. The update will provide additional functionality to the current registrant portal, add an applicant portal for future registrants, and update the public register.
Current registrants are required to reset their password by accessing the registrant portal from the PEICP website, and clicking on "forgot password." A new temporary password will be emailed to the email address on file with the College. The "registrant login" button at the top of the PEICP homepage will link you to the updated portal.
Any current bookmarks or favourites tabs linking to the PEICP registrant portal in internet browsers should be updated.
Please forward any questions to email@example.com or call the PEICP office at 902-628-3561.
Final Recommendations for Brimonidine Tartrate Opthalmic Solution in Concentrations up to and Including 0.025%
The interim recommendations made by the National Drug Scheduling Advisory Committee (NDSAC) on September 18, 2022 that:
Brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%, used for the relief of redness of the eye due to minor eye irritations caused by environmental allergies, dryness and fatigue for adults of 18 years and older remain in Schedule III
Brimonidine or its salts, except when sold as brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%, used for the relief of redness of the eye due to minor eye irritations caused by environmental allergies, dryness and fatigue for adults of 18 years and older will remain in Schedule I (as per the Prescription Drug List)
were finalized effective November 10, 2022. Final approval of the interim recommendations was made by NAPRA’s Board of Directors. In this case, NAPRA did not receive any comments during the 30-day review period.
Compounding Children's and Infant's Acetaminophen and Ibuprofen During Shortage
The College of Pharmacists of British Columbia released information last week surrounding an unfortunate compounding incident in a pharmacy in BC. Compounded acetaminophen liquid was mislabelled with the incorrect concentration/strength and provided to several patients with dosing directions based on the incorrect concentration/strength. Patient-specific information was not collected at the time of dispensing, leading to potential delay in recalling the mislabelled medication.
During the time of children’s and infant’s acetaminophen and ibuprofen shortage, Health Canada does not object to compounding of these products without a prescription but within a patient-healthcare professional relationship. Health Canada recommends that, at the pharmacy level, appropriate documentation is maintained to demonstrate a patient-healthcare professional relationship. In PEI, pharmacy professionals must compound products in accordance with the NAPRA Model Standards for Pharmacy Compounding of Non-sterile Preparations and the accompanying PEICP Guidance Document.
This incident offers several points of reflection for pharmacy professionals in PEI. Compounding is a high-risk activity. All compounded products must be provided in a manner that meets the minimum standards outlined in the NAPRA Model Standards, including:
Pharmacies must complete risk assessments, maintain master formulation records, maintain compounding records for each compound dispensed, and maintain batch records as applicable.
Pharmacies must have a procedure for the recall of compounded products which includes documentation to ensure traceability of all ingredients included in non-sterile compounded products.
Pharmacies must have an established policy for labelling and packaging that is consistent with the requirements outlined in the NAPRA Model Standards and the Pharmacy Act General Regulations. The label and supplementary label must provide all information required for proper use of the compounded preparation by the patient or for safe administration by a third party.
Given that several available acetaminophen compounding formulas have concentrations/strengths different than those typically commercially available, it is important that the pharmacist have a conversation with the patient or patient's representative to ensure understanding of correct dosing.
Visiting the PEICP Office
If you need to visit the College office, please email firstname.lastname@example.org or call 902-628-3561 to make an appointment.